DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: Community Center
Online groups, photo galleries and blogs
Clinical Challenges: Sickle Cell Management in the ED
The most common complication of sickle cell disease (SCD) is a vaso-occlusive crisis. The sudden nature of these crises, marked by intermittent, unexpected episodes of severe pain, leads most SCD patients to turn to the emergency department (ED) for care. In a 1997 study, for example, researchers found that 85.7% of hospital admissions for SCD came through the ED. And not much has changed since then.
A more recent study out of California found that out of a cohort of 4,636 patients with SCD, 88% had one or more treat-and-release visits to an ED during 2005 and 2014. And in 2005 alone, 35% of those patients had one to three treat-and-release visits, 9% had four to 10 visits, and 3% had >11 visits.
+myBinderRelated Content
-
people & placesNationwide Children’s HospitalThe Comprehensive Sickle Cell and Thalas...
-
news & eventsL-glutamine Oral Powder Significantly Reduces Acute Complications of Sickle Cell DiseaseApproved by the US Food and Drug...
-
education & researchStigma and pain in adolescents hospitalized for sickle cell vasoocclusive pain episodesOBJECTIVES: Sickle cell disease (SCD) p...
-
news & eventsBluebird Bio Presents Data From LentiGlobin Gene Therapy TrialBluebird Bio’s investigational gene th...
-
education & researchRandomized Feasibility Trial to Improve Hydroxyurea Adherence in Youth Ages 10–18 Years Through Community Health W...Introduction: The main therapeutic int...
-
news & eventsSCDF: BabySteps Parent Education MeetingBabySteps is a FREE monthly program for ...
-
news & eventsMen Living Well with Sickle Cell Guys Night OutMen with sickle cell disease open up can...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.